探讨血清 CA125 的糖基化。

NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Mount Merrion, Blackrock, Dublin 4, Ireland.

Int J Mol Sci. 2013 Jul 26;14(8):15636-54. doi: 10.3390/ijms140815636.

Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer.

卵巢癌是影响女性的最致命妇科癌症。CA125 是最广泛用于卵巢癌的生物标志物，但它缺乏灵敏度和特异性。在这里，我们探讨了卵巢癌患者血清和健康对照者血清中 CA125 糖基化的差异。我们发现患者血清中的 CA125 N-聚糖与对照组存在差异。这些差异包括核心岩藻糖基化双天线单唾液酸化聚糖的增加，以及与对照组相比患者中大多数双天线和非岩藻糖基化聚糖的减少。因此，CA125 糖基化状态的测量可能为卵巢癌患者提供更特异的生物标志物。